Endo, Fish, others...What Strategy will come to light at BofA Presentation Wednesday?
Not one mention of need for $50+ million at April 29 CC. Having $37 million in cash what drove the need for ~$100 million? PINPOINT and LUNA market needs were discussed but no indication of need to ramp up ongoing strategy. Something big, but what? I have express in other previous Board Messages but I would value other opinions to test mine or propose others.
Having been an investor in Biotech for decades, I have seen many medical companies go get the cash when the cash was being made available at a reasonable price. This might very well be the case in this situation. SEC regulations would prohibit the company from making any dramatic comments at the BofA conference, unless they first put out a press release.
I am hoping that the reaction to their products in the marketplace is better then expected , forcing them to both accelerate and increase their efforts related to expanding the salesforce and manufacturing capacity. This reason fits snugly with CC comments and the Pillar and MD Anderson comments. Certainly there was no existing pressure stemming from large negative cash flows. My conclusion is whatever the reasons were they were probably posttive ones.
Your thoughts are similar to mine. I don't expect a dramatic announcement but an indication that in light of the newly released PILLAR and MDA and hopefully ,...marketing responses to these papers... The last would be the most important as an indicator for what I'm lookng for.
Short of a dramatic announcement which I highly doubt, I'm not expecting any specifics. Probably we'll hear the usual stonewalling about being prepared for whatever comes along, plus what we already know about ramping up LUNA and Pinpoint. I'm sure Cannacord is pleased, however!